Costs and Outcome Among Patients With Chronic Myelogenous Leukemia (CML) Receiving Dasatinib or Nilotinib as First or Second Line Therapy in a Commercial and Medicare Population
Latest Information Update: 26 Mar 2015
At a glance
- Drugs Dasatinib (Primary) ; Nilotinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 19 Feb 2015 New trial record